Dermatology preclinical efficacy Imavita

Development of active ingredients in the dermatology domain can be accelerated by the use of dermatology models / preclinical models and imaging (in vivo or ex vivo).

Imavita works in the following skin pathologies:


Wound Healing Preclinical Models

Induced wounds (thermal / mechanical / chemical induction) in rodents (diabetic / non diabetic) & non rodent large animals
In vivo and ex vivo imaging
Details of wound healing preclinical models


Atopic Dermatitis Preclinical Models

Induced AD in rodents (allergen / hapten induced models)
In vivo and ex vivo imaging
Details of AD preclinical models

Preclinical models Imavita


Psoriasis Preclinical Models

Immunomodulator induction
In vivo and ex vivo imaging
Details of psoriasis preclinical models


Acne Preclinical Models

Spontaneous pathology
In vivo and ex vivo imaging
Details of acne preclinical models


Rosacea Preclinical Models

Induced pathology in murine model
In vivo and ex vivo imaging
Details of rosacea preclinical models

For additional informations on preclinical models in the area of dermatology, please inquire

Dermatology Drugs Market Evolution

Dermatology drugs market is expected to reach $34.5 billion by 2023, increasing personal spending, strong pipeline of dermatological drugs, and growing awareness about skin diseases are the key factors boosting the demand for dermatology drugs globally.

On the basis of treatment, the dermatology drugs market has been categorized into topical corticosteroids, retinoids, biologics, calcineurin inhibitors, antihistamines, hormonal therapy, and others. Among these, biologics are expected to be the fastest growing category, advancing at a growth rate of 9.1% during the forecast period.

Based on drug, the dermatology drugs market has been mainly classified into Humira, Remicade, Otezla, Stelara, Enbrel, Cosentyx, Neoral, Taltz, Cubicin, Canesten, Zyvox, Dupixent, Protopic, Valtrex, and Eucrisa. Of these, Humira witnessed the highest demand in the market, majorly among patients suffering from psoriasis.

Major therapy areas of dermatology drugs include psoriasis, atopic dermatitis, acne, rosacea, acne scars, and skin cancer.